Founded in 2012 as a biotechnology company focused on stem cell and immunotherapies for specialty niche treatments.
Fully reporting and trades publicly under the symbol: RGBP
Focused on immuno-oncology, stem cell/cancer stem cell, gene silencing
Currently 2 Investigational New Drug applications (IND) filed with the FDA
Three products in preclinical development based on the newly discovered cancer stem cell gene target
INTELLECTUAL PROPERTY | REGEN BIOPHARMA, INC
Regen licensed from Benitech BioPharma, on August 8, 2013, the use of its ddRNA portfolio for gene silencing for use in the field of blocking IDO expression in cancer. Benitec's licence to Regen covers the application of ddRNAi to silence indoleamine 2,3 -- dioxygenase (IDO) in Dendritic Cells. IDO is associated with immune-suppression and is over-expressed in cancer. Regen has produced pre-clinical evidence that modification of these cells using ddRNAi targeting the silencing of IDO should significantly enhance their efficacy as anti-cancer vaccine agents. A peer-reviewed publication describing this work was published in the February 2013 issue of the International Journal of Cancer (Zheng et al. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. Int J Cancer. 2013 Feb 15;132(4):967-77).
Intellectual Property Licensed from Benitec Covering Silencing of IDO Gene in Cancer
Visit us on Twitter
Regen BioPharma :: Fast Forwarding Stem Cell Medicine
Copyright Regen BioPharma, Inc. 2015